TY  - JOUR
AU  - Maldonado-Perez, Noelia
AU  - Tristan-Manzano, Maria
AU  - Justicia-Lirio, Pedro
AU  - Martinez-Planes, Elena
AU  - Muñoz, Pilar
AU  - Pavlovic, Kristina
AU  - Cortijo-Gutierrez, Marina
AU  - Blanco-Benitez, Carlos
AU  - Castella, Maria
AU  - Juan, Manel
AU  - Wenes, Mathias
AU  - Romero, Pedro
AU  - Molina-Estevez, Francisco J
AU  - Marañon, Concepcion
AU  - Herrera, Concha
AU  - Benabdellah, Karim
AU  - Martin, Francisco
PY  - 2022
DO  - 10.3389/fimmu.2022.1011858
UR  - http://hdl.handle.net/10668/20594
T2  - Frontiers in immunology
AB  - Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment...
LA  - en
PB  - Frontiers Research Foundation
KW  - CAR-T cells
KW  - CRISPR/Cas9
KW  - TCRKO
KW  - Large deletions
KW  - Lymphoma
KW  - Off-the-shelf
KW  - Safety
KW  - Humans
KW  - Receptors, Chimeric Antigen
KW  - Immunotherapy, Adoptive
KW  - T-Lymphocytes
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Lymphoma, B-Cell
TI  - Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
TY  - research article
VL  - 13
ER  -